1492 Capital Management’s CASI Pharmaceuticals CASI Stock Holding History

1492 Capital Management’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,876	Closed	-$94K	–	105
2021 Q3	$94K	Sell	7,876 -98	-1%	-$1.32K	0.05%	106
2021 Q2	$124K	Hold	7,974	–	–	0.06%	109
2021 Q1	$191K	Buy	+7,974	New	+$224K	0.11%	93

Other funds holding CASI

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

1492 Capital Management's CASI Position: Q4 2021 in Review

1492 Capital Management sold out of CASI Pharmaceuticals (CASI) in Q4 2021, closing a stake of 7,876 shares — an estimated $94K sold.

1492 Capital Management first reported a position in CASI in Q1 2021 and held it in 3 quarters. The position peaked at $191K in Q1 2021. 51 funds tracked by Wall St. Rank hold CASI as of Q4 2021.

1492 Capital Management reported no remaining CASI Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
1492 Capital Management sold 7,876 CASI Pharmaceuticals shares in Q4 2021, an estimated $94K.
1492 Capital Management first reported a position in CASI Pharmaceuticals in Q1 2021 and held it in 3 quarters.
1492 Capital Management's CASI Pharmaceuticals position peaked at $191K in Q1 2021.
51 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q4 2021.

Based on 1492 Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.